An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS) - ND
- Conditions
- Thrombocytopenic Subjects with Myelodysplastic Syndrome (MDS)MedDRA version: 9.1Level: PTClassification code 10028533
- Registration Number
- EUCTR2007-001516-24-IT
- Lead Sponsor
- Amgen Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 250
Subject completed a romiplostim study for the treatment of thrombocytopenia in subjects with MDS Demographic: Eastern Cooperative Oncology ( ECOG) performance status of 0-2 Laboratory: Subject had a platelet count of ≤ 50 x 109/L since the final dose of investigational product in the parent study General: Subject or his/her legally acceptable representative provided written informed consent before any study-specific procedures were initiated
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Subject has been diagnosed with AML or has a blast count mag uguale 10 pc by peripheral blood or bone marrow biopsy Subject has prior history of leukemia Prior history of bone marrow or stem cell transplantation Prior malignancy (other than in situ cervical cancer, controlled prostate cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for mag uguale 3 years before randomization Active or uncontrolled infections Unstable angina, congestive heart failure [NYHA > class II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past year History of venous thrombosis that currently requires anti-coagulation therapy Medications: Received IL-11 within 4 weeks of screening Subject previously received a thrombopoietic growth factor (other than romiplostim) Known hypersensitivity to any recombinant E coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune) General: Subject currently is enrolled in or has not yet completed at least four weeks since ending investigational device or drug study(s) (other than romiplostim), or subject is receiving other investigational agent(s) Subject of child-bearing potential is evidently pregnant (eg, positive HCG test) or is breast feeding Subject is not using adequate contraceptive precautions Subject has any kind of disorder that compromises his/her ability to give written informed consent (and does not have a legally acceptable representative; or is unable to comply with study procedures
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The primary objective is to provide long-term safety data for the use of romiplostim in thrombocytopenic subjects with myelodysplastic syndromes (MDS).;Secondary Objective: The secondary objective is to evaluate the effectiveness of romiplostim with respect to platelet response, transfusion, and bleeding events in the treatment of thrombocytopenic subjects with MDS.;Primary end point(s): L`endpoint primario riguarda l`incidenza di tutti gli eventi avversi compresi cambiamenti clinicamente significativi dei valori di laboratorio e l`incidenza della formazione di anticorpi.
- Secondary Outcome Measures
Name Time Method